Halil Lutfi Canat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Halil Lutfi Canat has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
- Hasan Anıl Atalay
Department of Urology, Okmeydanı Training and Research Hospital, Sisli-Istanbul, Turkey
20 shared publications - Osman Can
Department of Urology, Basaksehir Çam Sakura City Hospital, Istanbul, Turkey
14 shared publications - Akif Erbin
Health Science University, Basaksehir Çam Sakura City Hospital, Department of Urology, Istanbul, Turkiye
12 shared publications - Alper Otunctemur
Department of Urology, Cemil Tascioglu City Hospital, University of Health Sciences, Istanbul, Turkey
10 shared publications - Çağrı Şevik
Department of Urology, Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey
10 shared publications - Emin Taha Keskin
Department of Urology, Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey
9 shared publications
Latest Publications
- 1 November 2026
- Published by Wiley in The Prostate
Prostatic Enlargement in Acromegaly Despite Preserved Lower Urinary Tract Function: A Cross‐Sectional Comparative Study
Background: Acromegaly is characterized by organomegaly driven by chronic GH/IGF‐1 excess, and the prostate gland may be affected as part of this generalized organ enlargement. Although prostatic enlargement has been documented in previous studies, whether it is accompanied by symptomatic or functional impairment and its potential impact on quality of life remain unclear. This study aimed to evaluate prostate‐related changes in male patients with active and remitting acromegaly compared to healthy controls, and to assess their association with lower urinary tract symptoms, mood, and quality of life. Methods: This cross‐sectional study included 57 male patients with acromegaly (25 active, 32 in remission) and 24 healthy male controls of comparable age and BMI. All participants underwent transabdominal prostate ultrasonography, uroflowmetry, and completed the IPSS, SF‐36, PHQ‐9, GAD‐7, and FSS questionnaires. The AcroQoL was administered to the acromegaly group. Correlations between IGF‐1 levels and prostate parameters were analyzed using Spearman's correlation. Results: Patients with acromegaly had a larger median prostate volume (30 vs. 20 mL, p = 0.03), more frequently had a prostate volume exceeding 30 mL (47% vs. 11%, p = 0.004), and more frequently had prostatic calcification (31% vs. 5%, p = 0.03) than controls, despite lower testosterone levels. Within the acromegaly group, a prostate volume exceeding 30 mL was more frequent in active disease than in remission (64% vs. 33%, p = 0.02), whereas median prostate volume did not differ significantly (31 vs. 24.5 mL, p = 0.1). IGF‐1 was correlated with free PSA (rho = 0.29, p = 0.03) but not with total prostate volume (rho = 0.09, p = 0.53). Calcification rates did not differ by remission status. No significant differences were observed in IPSS scores, uroflowmetry parameters, SF‐36, PHQ‐9, GAD‐7, or AcroQoL between groups. Conclusion: Male patients with acromegaly have larger prostate volumes and more frequent prostatic calcification than controls; prostatic enlargement was more frequent in active disease, whereas calcification did not differ by remission status. These structural alterations were not accompanied by differences in lower urinary tract symptoms, uroflowmetry parameters, or quality of life, suggesting that dedicated urologic surveillance may not be warranted in asymptomatic middle‐aged patients.
- 1 November 2026
- Published by Wiley in The Prostate
Prostatic Enlargement in Acromegaly Despite Preserved Lower Urinary Tract Function: A Cross‐Sectional Comparative Study
Background: Acromegaly is characterized by organomegaly driven by chronic GH/IGF‐1 excess, and the prostate gland may be affected as part of this generalized organ enlargement. Although prostatic enlargement has been documented in previous studies, whether it is accompanied by symptomatic or functional impairment and its potential impact on quality of life remain unclear. This study aimed to evaluate prostate‐related changes in male patients with active and remitting acromegaly compared to healthy controls, and to assess their association with lower urinary tract symptoms, mood, and quality of life. Methods: This cross‐sectional study included 57 male patients with acromegaly (25 active, 32 in remission) and 24 healthy male controls of comparable age and BMI. All participants underwent transabdominal prostate ultrasonography, uroflowmetry, and completed the IPSS, SF‐36, PHQ‐9, GAD‐7, and FSS questionnaires. The AcroQoL was administered to the acromegaly group. Correlations between IGF‐1 levels and prostate parameters were analyzed using Spearman's correlation. Results: Patients with acromegaly had a larger median prostate volume (30 vs. 20 mL, p = 0.03), more frequently had a prostate volume exceeding 30 mL (47% vs. 11%, p = 0.004), and more frequently had prostatic calcification (31% vs. 5%, p = 0.03) than controls, despite lower testosterone levels. Within the acromegaly group, a prostate volume exceeding 30 mL was more frequent in active disease than in remission (64% vs. 33%, p = 0.02), whereas median prostate volume did not differ significantly (31 vs. 24.5 mL, p = 0.1). IGF‐1 was correlated with free PSA (rho = 0.29, p = 0.03) but not with total prostate volume (rho = 0.09, p = 0.53). Calcification rates did not differ by remission status. No significant differences were observed in IPSS scores, uroflowmetry parameters, SF‐36, PHQ‐9, GAD‐7, or AcroQoL between groups. Conclusion: Male patients with acromegaly have larger prostate volumes and more frequent prostatic calcification than controls; prostatic enlargement was more frequent in active disease, whereas calcification did not differ by remission status. These structural alterations were not accompanied by differences in lower urinary tract symptoms, uroflowmetry parameters, or quality of life, suggesting that dedicated urologic surveillance may not be warranted in asymptomatic middle‐aged patients.
- Open Access
- 22 October 2026
- Published by Pensoft Publishers in Folia Medica
- Vol. 68 (5) , e165007
A case of rare metanephric neoplasm resembling renal cell carcinoma: metanephric stromal tumor
Metanephric neoplasms (MNs) represent an uncommon subset of benign renal tumors, encompassing entities such as metanephric adenoma, metanephric stromal tumor (MST), and metanephric adenofibroma. Despite the limitations of radiological modalities in accurately differentiating these lesions, their characteristic histopathological architecture and unique immunohistochemical markers are crucial for establishing a definitive diagnosis and distinguishing them from other renal malignancies. In this case report, we describe the diagnostic and treatment process for a 25-year-old woman who was incidentally diagnosed with an MST after undergoing a radical nephrectomy, backed by an analysis of recent research.
- 22 October 2026
- Published by Pensoft Publishers in Folia Medica
- Vol. 68 (5) , e165007
Open AccessA case of rare metanephric neoplasm resembling renal cell carcinoma: metanephric stromal tumor
Metanephric neoplasms (MNs) represent an uncommon subset of benign renal tumors, encompassing entities such as metanephric adenoma, metanephric stromal tumor (MST), and metanephric adenofibroma. Despite the limitations of radiological modalities in accurately differentiating these lesions, their characteristic histopathological architecture and unique immunohistochemical markers are crucial for establishing a definitive diagnosis and distinguishing them from other renal malignancies. In this case report, we describe the diagnostic and treatment process for a 25-year-old woman who was incidentally diagnosed with an MST after undergoing a radical nephrectomy, backed by an analysis of recent research.
- 30 September 2026
- Published by Endouroloji Dernegi in Endouroloji Bulteni
- Vol. 18 (3) , 176-186
Beyond Statistical Accuracy: Decision Curve Analysis and Single-Center Independent Validation of the SHA.LIN Score for PCNL Outcomes
Objective: To perform a single-center independent validation of the SHA.LIN score and compare its predictive accuracy and clinical net benefit with the Guy’s Stone Score (GSS), S.T.O.N.E. score, and CROES nomogram in a large cohort of patients undergoing percutaneous nephrolithotomy (PCNL).Materials and Methods: We retrospectively analyzed 271 adult patients undergoing PCNL between 2020 and 2025. Stone-free status (SFS) was defined as the absence of stones or asymptomatic fragments <4 mm on non-contrast computed tomography at 1 month. Predictive performance was assessed using area under the curve (AUC), calibration plots, and Decision Curve Analysis (DCA).Results: The SFS rate was 73.1%. The CROES nomogram demonstrated the highest predictive accuracy (AUC: 0.802, 95% CI: 0.765–0.839), followed by the SHA.LIN score (AUC: 0.756, 95% CI: 0.715–0.797). The SHA.LIN score significantly outperformed both GSS (AUC: 0.719, p=0.023) and S.T.O.N.E. (AUC: 0.690, p<0.0001). In both univariate and multivariable analyses, the CROES nomogram and SHA.LIN score emerged as significant independent predictors of stone-free status, whereas Guy and STONE scores failed to retain significance after multivariable adjustment. In DCA, the SHA.LIN score showed superior net clinical benefit compared with GSS and S.T.O.N.E. across threshold probabilities between 40% and 80%.Conclusion: The SHA.LIN score is a reliable, independently validated single-center tool for predicting PCNL outcomes. Although the CROES nomogram demonstrates high statistical accuracy, the SHA.LIN score provides superior clinical utility and net benefit in decision curve analysis. Furthermore, CROES and SHA.LIN scores remained independent predictors of stone-free status, whereas Guy and STONE scores failed to demonstrate independent predictive value in multivariable analyses. Further prospective studies with larger cohorts are warranted to validate these findings.
- 30 September 2026
- Published by Endouroloji Dernegi in Endouroloji Bulteni
- Vol. 18 (3) , 176-186
Beyond Statistical Accuracy: Decision Curve Analysis and Single-Center Independent Validation of the SHA.LIN Score for PCNL Outcomes
Objective: To perform a single-center independent validation of the SHA.LIN score and compare its predictive accuracy and clinical net benefit with the Guy’s Stone Score (GSS), S.T.O.N.E. score, and CROES nomogram in a large cohort of patients undergoing percutaneous nephrolithotomy (PCNL).Materials and Methods: We retrospectively analyzed 271 adult patients undergoing PCNL between 2020 and 2025. Stone-free status (SFS) was defined as the absence of stones or asymptomatic fragments <4 mm on non-contrast computed tomography at 1 month. Predictive performance was assessed using area under the curve (AUC), calibration plots, and Decision Curve Analysis (DCA).Results: The SFS rate was 73.1%. The CROES nomogram demonstrated the highest predictive accuracy (AUC: 0.802, 95% CI: 0.765–0.839), followed by the SHA.LIN score (AUC: 0.756, 95% CI: 0.715–0.797). The SHA.LIN score significantly outperformed both GSS (AUC: 0.719, p=0.023) and S.T.O.N.E. (AUC: 0.690, p<0.0001). In both univariate and multivariable analyses, the CROES nomogram and SHA.LIN score emerged as significant independent predictors of stone-free status, whereas Guy and STONE scores failed to retain significance after multivariable adjustment. In DCA, the SHA.LIN score showed superior net clinical benefit compared with GSS and S.T.O.N.E. across threshold probabilities between 40% and 80%.Conclusion: The SHA.LIN score is a reliable, independently validated single-center tool for predicting PCNL outcomes. Although the CROES nomogram demonstrates high statistical accuracy, the SHA.LIN score provides superior clinical utility and net benefit in decision curve analysis. Furthermore, CROES and SHA.LIN scores remained independent predictors of stone-free status, whereas Guy and STONE scores failed to demonstrate independent predictive value in multivariable analyses. Further prospective studies with larger cohorts are warranted to validate these findings.
- 1 August 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (10) , 9576
ASO Visual Abstract: Who is at Risk of Residual Tumor and Pathologic Upstaging at Second TURBT in Non–Muscle-Invasive Bladder Cancer?
- 1 August 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (10) , 9576
ASO Visual Abstract: Who is at Risk of Residual Tumor and Pathologic Upstaging at Second TURBT in Non–Muscle-Invasive Bladder Cancer?
- 27 July 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (10) , 9517-9525
Who is at Risk of Residual Tumor and Pathologic Upstaging at a Second TURBT in Non–Muscle-Invasive Bladder Cancer?
- 27 July 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (10) , 9517-9525
Who is at Risk of Residual Tumor and Pathologic Upstaging at a Second TURBT in Non–Muscle-Invasive Bladder Cancer?
- Open Access
- 2 July 2026
- Published by Oxford University Press (OUP) in Sexual Medicine
- Vol. 14 (5)
Validation of the Turkish version of the ANDROTEST for detecting male hypogonadism in patients with sexual dysfunction
Background: Male hypogonadism is an important endocrine cause of sexual dysfunction, yet symptom-based screening tools require cultural and linguistic validation to ensure their reliability across different populations. Aim: To evaluate the diagnostic performance, reliability, and validity of the Turkish version of the ANDROTEST in men presenting with sexual dysfunction. Methods: This prospective observational study included men aged 18-80 years presenting to the andrology outpatient clinic with symptoms of sexual dysfunction between February and November 2025. A control group consisted of age-matched individuals without clinical suspicion of hypogonadism or conditions affecting gonadal function. Participants completed the Turkish versions of Beck Depression Inventory (BDI) and the International Index of Erectile Function (IIEF). The ANDROTEST was translated and culturally adapted using a forward–backward translation process. Diagnostic performance was evaluated using receiver operating characteristic curve analysis, while test–retest reliability was assessed using the intraclass correlation coefficient (ICC). Multivariable logistic regression analysis was performed to identify independent predictors of hypogonadism. Outcomes: The primary outcome was the diagnostic performance of the Turkish ANDROTEST for identifying hypogonadism. Results: A total of 246 participants were included (120 controls and 126 patients with hypogonadism). Hypogonadal patients demonstrated significantly higher body mass index, triglycerides, total cholesterol, low-density lipoprotein cholesterol, and BDI, whereas total testosterone, free testosterone, sex hormone-binding globulin, high-density lipoprotein cholesterol, IIEF scores, and testicular volumes were significantly lower (all P < .05). The Turkish ANDROTEST demonstrated excellent diagnostic performance with an area under the curve of 0.980 (95% CI: 0.958-0.994). The optimal cut-off value of 11 yielded a sensitivity of 95.2% and specificity of 95.0%. In multivariable analysis, ANDROTEST remained an independent predictor of hypogonadism (adjusted OR 1.80, P = .009). Test–retest reliability was excellent (ICC = 0.99), and strong correlations were observed between the ANDROTEST score and IIEF scores, total testosterone levels, and depression scores (all P < .001). Clinical Implications: The Turkish version of the ANDROTEST may serve as a practical screening tool for identifying men at risk of hypogonadism in routine clinical practice. Strengths and Limitations: Strengths include the prospective design and comprehensive evaluation of psychometric and diagnostic performance. Limitations include the single-center design and the case–control structure, which may overestimate diagnostic performance. Conclusion: The Turkish version of the ANDROTEST demonstrated excellent diagnostic performance and strong reliability for identifying male hypogonadism in men with sexual dysfunction, supporting its potential utility as a culturally adapted screening tool in clinical practice.
- 2 July 2026
- Published by Oxford University Press (OUP) in Sexual Medicine
- Vol. 14 (5)
Open AccessValidation of the Turkish version of the ANDROTEST for detecting male hypogonadism in patients with sexual dysfunction
Background: Male hypogonadism is an important endocrine cause of sexual dysfunction, yet symptom-based screening tools require cultural and linguistic validation to ensure their reliability across different populations. Aim: To evaluate the diagnostic performance, reliability, and validity of the Turkish version of the ANDROTEST in men presenting with sexual dysfunction. Methods: This prospective observational study included men aged 18-80 years presenting to the andrology outpatient clinic with symptoms of sexual dysfunction between February and November 2025. A control group consisted of age-matched individuals without clinical suspicion of hypogonadism or conditions affecting gonadal function. Participants completed the Turkish versions of Beck Depression Inventory (BDI) and the International Index of Erectile Function (IIEF). The ANDROTEST was translated and culturally adapted using a forward–backward translation process. Diagnostic performance was evaluated using receiver operating characteristic curve analysis, while test–retest reliability was assessed using the intraclass correlation coefficient (ICC). Multivariable logistic regression analysis was performed to identify independent predictors of hypogonadism. Outcomes: The primary outcome was the diagnostic performance of the Turkish ANDROTEST for identifying hypogonadism. Results: A total of 246 participants were included (120 controls and 126 patients with hypogonadism). Hypogonadal patients demonstrated significantly higher body mass index, triglycerides, total cholesterol, low-density lipoprotein cholesterol, and BDI, whereas total testosterone, free testosterone, sex hormone-binding globulin, high-density lipoprotein cholesterol, IIEF scores, and testicular volumes were significantly lower (all P < .05). The Turkish ANDROTEST demonstrated excellent diagnostic performance with an area under the curve of 0.980 (95% CI: 0.958-0.994). The optimal cut-off value of 11 yielded a sensitivity of 95.2% and specificity of 95.0%. In multivariable analysis, ANDROTEST remained an independent predictor of hypogonadism (adjusted OR 1.80, P = .009). Test–retest reliability was excellent (ICC = 0.99), and strong correlations were observed between the ANDROTEST score and IIEF scores, total testosterone levels, and depression scores (all P < .001). Clinical Implications: The Turkish version of the ANDROTEST may serve as a practical screening tool for identifying men at risk of hypogonadism in routine clinical practice. Strengths and Limitations: Strengths include the prospective design and comprehensive evaluation of psychometric and diagnostic performance. Limitations include the single-center design and the case–control structure, which may overestimate diagnostic performance. Conclusion: The Turkish version of the ANDROTEST demonstrated excellent diagnostic performance and strong reliability for identifying male hypogonadism in men with sexual dysfunction, supporting its potential utility as a culturally adapted screening tool in clinical practice.
- Open Access
- 30 June 2026
- Published by Pera Yayıncılık Hizmetleri in The New Journal of Urology
- Vol. 21 (2) , 96
High-Grade Urothelial Carcinoma with Sarcomatoid Differentiation: A Rare Case Presenting with Colonic Metastasis
Objective: Urothelial carcinoma with sarcomatoid differentiation is an uncommon but highly aggressive variant of bladder cancer, often diagnosed at advanced stages and associated with poor outcomes. Colonic metastasis from bladder carcinoma is extremely rare, making this case noteworthy. Case presentation: A 68-year-old male presented with macroscopic hematuria and dysuria. Imaging revealed a bladder mass invading the perivesical tissue. Transurethral biopsy confirmed high-grade urothelial carcinoma with sarcomatoid differentiation. During preoperative evaluation, colonoscopy revealed an ulcerated mass in the ascending colon, confirmed as metastatic carcinoma with similar sarcomatoid features. The patient underwent radical cystectomy and right hemicolectomy. Despite surgery and planned chemotherapy, the patient died postoperatively due to clinical deterioration. Conclusions: This case underscores the aggressive nature of sarcomatoid urothelial carcinoma and highlights the potential for rare metastatic patterns, emphasizing the need for multidisciplinary management in atypical presentations.
- 30 June 2026
- Published by Pera Yayıncılık Hizmetleri in The New Journal of Urology
- Vol. 21 (2) , 96
Open AccessHigh-Grade Urothelial Carcinoma with Sarcomatoid Differentiation: A Rare Case Presenting with Colonic Metastasis
Objective: Urothelial carcinoma with sarcomatoid differentiation is an uncommon but highly aggressive variant of bladder cancer, often diagnosed at advanced stages and associated with poor outcomes. Colonic metastasis from bladder carcinoma is extremely rare, making this case noteworthy. Case presentation: A 68-year-old male presented with macroscopic hematuria and dysuria. Imaging revealed a bladder mass invading the perivesical tissue. Transurethral biopsy confirmed high-grade urothelial carcinoma with sarcomatoid differentiation. During preoperative evaluation, colonoscopy revealed an ulcerated mass in the ascending colon, confirmed as metastatic carcinoma with similar sarcomatoid features. The patient underwent radical cystectomy and right hemicolectomy. Despite surgery and planned chemotherapy, the patient died postoperatively due to clinical deterioration. Conclusions: This case underscores the aggressive nature of sarcomatoid urothelial carcinoma and highlights the potential for rare metastatic patterns, emphasizing the need for multidisciplinary management in atypical presentations.